Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics
Merck Found To Have An 85% Share Of The Temozolomide Market
Merck has agreed to discontinue a “predatory strategy” for the company’s Temodal (temozolomide) oncology brand in Austria that kept generics out of the market, including by supplying the brand below cost price, under commitments offered to the country’s competition watchdog.
You may also be interested in...
The European Commission is investigating whether Teva “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.
Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.
Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.